Abstract:Background and Purpose NLRP3 inflammasome activation is involved in many inflammatory diseases, however, no small‐molecule inhibitors of NLRP3 have been clinically used so far. Discovery of natural NLRP3 inhibitors may be beneficial to the design and development of molecules targeting NLRP3. Alantolactone (ALA) is a natural compound isolated from a traditional Chinese medicinal plant with anti‐inflammatory activity, but the precise target of ALA remains unclear. Experimental Approach The inhibitory activity of 150 natural compounds against NLRP3‐driven IL‐1β production was screened in macrophages. Mice models of gouty arthritis and acute lung injury were used to determine the efficacy of the potential compound. Key Results Among 150 compounds in an in‐house natural products bank, ALA was found to possess the highest inhibitory activity against LPS + ATP‐induced IL‐1β production in macrophages. We demonstrated that ALA suppressed the IL‐1β secretion, the caspase‐1 activation, and pyroptosis in LPS + ATP‐challenged macrophages. Further studies showed that ALA directly bound to the NACHT domain of NLRP3 to inhibit the activation and assembly of NLRP3 inflammasome. The molecular simulation showed that Arg335 in NLRP3 might be a critical residue for ALA binding, leading to suppression of NLRP3‐NEK7 interaction. The in vivo studies validated that ALA significantly alleviated NLRP3‐driven inflammatory diseases, including acute lung injury and gouty arthritis. Conclusion and Implications In summary, we identified ALA as a natural inhibitor of NLRP3 inflammasome by directly targeting NLRP3 NACHT domain. ALA shows great potential in the treatment of NLRP3‐driven diseases and the development of novel NLRP3 inhibitors.

Discovery of Novel Biaryl Urea Derivatives Against IL-1β Release with Low Toxicity Based on NEK7 Inhibitor

A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout

Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis

Synthesis and Biological Evaluation of Novel Benzimidazole Derivatives and Analogs Targeting the NLRP3 Inflammasome

Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes

Discovery of alantolactone as a natural NLRP3 inhibitor to alleviate NLRP3‐driven inflammatory diseases in mice

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors

Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity

Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis

Discovery of NLRP3 Inhibitors Using Machine Learning: Identification of a Hit Compound to Treat NLRP3 Activation-Driven Diseases.

The discovery of quinoline derivatives, as NF-κB inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth